secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000885725-24-000075
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific resumes AVANT GUARD trial in drug-naïve persistent AFib patients
--------------------------------------------------------------------------------

- AVANT GUARD trial resumed after assessment of observations and DMC input.
- Study targets new population of drug-naïve patients with persistent atrial fibrillation.
- No financial impact or patient enrollment numbers disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000075/0000885725-24-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000075/bsx-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000885725-24-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer